Comparing two treatments for diabetic foot ulcers
Official title: A Randomized Double-blind Clinical Trial Comparing Hypochlorous Acid and Polyhexamethylene Biguanide in Treating Diabetic Foot Ulcers
Run by Vastra Gotaland Region · NCT05132179 · Data updated 2026-11-12
This study is testing which wound cleaner, Hypochlorous Acid or Polyhexamethylene biguanide, works better for healing diabetic foot ulcers in people over a period of up to 24 weeks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 202 (estimated) |
| Sponsor | Vastra Gotaland Region Government |
| Locations | 1 site (Uddevalla, Trollhattan) |
| Status | Recruiting |
| Started | February 1, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 7, 2024 |
| Trial ID | NCT05132179 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with diabetes and foot ulcers that have persisted for three weeks or more.
✕Probably not a fit
Patients with severe complications such as critically impaired circulation, recent myocardial infarction or stroke, or those requiring intensive care may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial involves 202 participants with diabetic foot ulcers who will be randomly assigned to receive either Hypochlorous Acid (HClO) or Polyhexamethylene biguanide (PHMB) for cleaning their wounds. The treatment will occur twice a week until the ulcers heal or for a maximum of 24 weeks. The primary goal is to determine which cleaning agent is more effective in achieving complete healing of the ulcers, while secondary objectives include assessing healing time, ulcer size, depth, antibiotic use, and quality of life. The study is designed to be double-blind and controlled to ensure unbiased results.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment options for diabetic foot ulcers, improving healing rates and patient outcomes.
How similar studies have gone: Previous studies have shown varying degrees of success with similar antimicrobial treatments, but this specific comparison of HClO and PHMB is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Informed consent obtained before trial-related activities, * Diabetes Mellitus type 1 or 2 or due to pancreatitis * Foot ulcer since 3 weeks or more * Ulcer surface area 9 mm2 or more * Age 18 years old or more Exclusion Criteria: * Persons in need of intensive care or dialysis * Persons in need of vascular intervention, critically impaired circulation (toe-pressure \< 30 mm Hg) * Event of myocardial infarction or stroke during the last three months * Debut of atrial fibrillation or heart failure during the last three months * Current treatment of malignancy * Treatment with corticosteroids with a dose corresponding to 50 mg Prednisolon * Severe wound infection according to International Working Group of Diabetic Foot, IWGDF at least two of following signs: body temperature \<36 C or \>38 C, heart rate \>90/minute, respiration rate \>20/minute, LPK \>12x10\^9/L * Planned changed residence in the coming 12 months requiring change of clinic for wound treatment during the follow-up time * Age under 18 years old * Diabetes of MOODY type * Current known pregnancy or planned pregnancy next 26 weeks * Participation in another clinical trial evaluating any treatment * Other reasons judged by the investigator that the patient is unsuitable for participation in the study
Where it's running
-
NU sjukvarden
Uddevalla, Trollhattan, Sweden Recruiting
Study contacts
- Principal investigator: Marcus Lind, Prof — University of Gothenburg, Sahlgrenska Academy
- Study coordinator: Karin Bergqvist, MD
- Email: karin.bergqvist@vgregion.se
- Phone: +46730961700
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BIOxHEAL plus standard care for nonhealing diabetic foot ulcers
A multicenter study tests whether applying BIOxHEAL, a placental-derived biologic, to stubborn diabetic foot ulcers helps more people heal when added to standard wound care.
-
Calcaneal Bone Marrow Cells in Foot/Ankle Surgery Patients
This observational study tests whether routine preoperative blood tests relate to the quality and behavior of mesenchymal stem cells from calcaneal bone marrow in adults undergoing foot or ankle surgery.
-
L-Carnitine as an add-on for healing diabetic foot ulcers
This study tests whether taking L-Carnitine helps wound healing in adults with diabetic foot ulcers, alongside standard diabetes and wound care.
-
THERAVEX Tissue Care Spray Plus for Healing of Skin Wounds and Ulcers
This observational review tests whether THERAVEX Tissue Care Spray Plus, used with standard wound care, helps heal various skin wounds and chronic ulcers in adults.
-
Pulsating electromagnetic field therapy for diabetic foot ulcers
This trial tests whether a PEMF device called CRAD ULCER X-01 helps heal chronic diabetic foot ulcers when added to standard wound care.
-
Transverse tibial bone transport to help heal chronic diabetic foot ulcers
This study tests a surgical approach called transverse tibial bone transport to see if it can help heal long‑lasting diabetic foot ulcers and prevent limb loss in adults with limited treatment options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.